MLTX Key Statistics, Chart & Performance
The current stock price of MLTX is 13.695 USD. In the past month the price decreased by -0.25%. In the past year, price decreased by -74.38%.
MLTX Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.43 | 407.98B | ||
| AMGN | AMGEN INC | 15.07 | 177.50B | ||
| GILD | GILEAD SCIENCES INC | 15.25 | 154.97B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.49 | 116.66B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.34 | 82.03B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 782 | 52.69B | ||
| INSM | INSMED INC | N/A | 37.61B | ||
| NTRA | NATERA INC | N/A | 31.92B | ||
| BIIB | BIOGEN INC | 10.56 | 25.94B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.06 | 21.65B | ||
| INCY | INCYTE CORP | 15.47 | 19.49B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.34B |
Related stock screener links
About MLTX
Company Profile
Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. The company is headquartered in Zug, Zug and currently employs 100 full-time employees. The company went IPO on 2020-10-20. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The firm develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.
Company Info
MOONLAKE IMMUNOTHERAPEUTICS
Dorfstrasse 29
Zug ZUG CH
Employees: 100
Phone: 41415108022
MOONLAKE IMMUNOTHERAPEUTICS / MLTX FAQ
Can you describe the business of MOONLAKE IMMUNOTHERAPEUTICS?
Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. The company is headquartered in Zug, Zug and currently employs 100 full-time employees. The company went IPO on 2020-10-20. The Firm is a clinical-stage biopharmaceutical company focused on the development of medicines for immunologic diseases, including inflammatory skin and joint diseases. The firm develops tri-specific nanobody Sonelokimab (SLK) which purpose is to target and penetrate difficult-to-reach inflamed tissues. SLK is a molecule with enhanced enrichment in deep skin & joints and binding of targets. SLK inhibits IL-17A and IL-17F inhibition to treat inflammatory diseases, by independently inhibiting the naturally-occurring IL-17 A/A, A/F and F/F dimers that drive inflammation in patients.
What is the stock price of MOONLAKE IMMUNOTHERAPEUTICS today?
The current stock price of MLTX is 13.695 USD. The price decreased by -0.98% in the last trading session.
What is the dividend status of MOONLAKE IMMUNOTHERAPEUTICS?
MLTX does not pay a dividend.
How is the ChartMill rating for MOONLAKE IMMUNOTHERAPEUTICS?
MLTX has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is MLTX stock listed?
MLTX stock is listed on the Nasdaq exchange.
What do analysts say about MOONLAKE IMMUNOTHERAPEUTICS (MLTX) stock?
24 analysts have analysed MLTX and the average price target is 19.22 USD. This implies a price increase of 40.35% is expected in the next year compared to the current price of 13.695.
Can you provide the market cap for MOONLAKE IMMUNOTHERAPEUTICS?
MOONLAKE IMMUNOTHERAPEUTICS (MLTX) has a market capitalization of 984.67M USD. This makes MLTX a Small Cap stock.
MLTX Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to MLTX. When comparing the yearly performance of all stocks, MLTX is a bad performer in the overall market: 71.48% of all stocks are doing better.
MLTX Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to MLTX. MLTX scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
MLTX Financial Highlights
Over the last trailing twelve months MLTX reported a non-GAAP Earnings per Share(EPS) of -3.32. The EPS decreased by -157.36% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -50.8% | ||
| ROE | -72.86% | ||
| Debt/Equity | 0.26 |
MLTX Forecast & Estimates
24 analysts have analysed MLTX and the average price target is 19.22 USD. This implies a price increase of 40.35% is expected in the next year compared to the current price of 13.695.